Atlantic Lipid Lowering Treatment Optimization Program

Last updated: July 30, 2025
Sponsor: Atlantic Health System
Overall Status: Active - Recruiting

Phase

N/A

Condition

High Cholesterol (Hyperlipidemia)

Familial Hypercholesterolemia

Dyslipidemia

Treatment

Supportive care

Clinical Study ID

NCT06439654
2096455
  • Ages 18-120
  • All Genders

Study Summary

Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the treatment of lipid disorders in those patients with abnormal lipid levels by improving access to resources at the primary care practice level and specialty level. We aim to develop a model for primary and secondary prevention that integrates guidelines for treatment at the practice level. Our primary objective is to identify high-risk patients by utilizing the electronic health record and partnering with patients' primary care providers to provide comprehensive medical management.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • LDL-C ≥160 mg/dL

  • Untreated LDL-C ≥190 with family history of CAD

  • Prior MI and currently without optimized lipid-lowering therapy

  • Family history of CAD in first degree relative

  • Personal history of CAD

  • Untreated triglycerides >500

  • Elevated Lp(a) and/or high calcium scores

  • Consenting individuals

Exclusion

Exclusion Criteria:

  • Individuals who are pregnant

  • Individuals who are incarcerated

  • Individuals with a terminal illness

  • Individuals who do not consent

Study Design

Total Participants: 250
Treatment Group(s): 1
Primary Treatment: Supportive care
Phase:
Study Start date:
July 01, 2024
Estimated Completion Date:
December 31, 2027

Study Description

This study will screen patients with LDL-C >160 mg/dL and with evidence of familial hypertension, reach out (using secure chat) to the attending practitioner of such patients and inform the practitioner of our comprehensive services to address FH. A study team member will inform the practitioner that one of the study team plans to reach out to their patient to inform the patient of the study. Unless one of the study team receives notification by the practitioner that they want to opt out of this service for their patients, and do not want further interaction, the patient will be informed of the study and the consent process.

The research question is: Will an innovative comprehensive outreach approach, in conjunction with the primary care provider, reduce LDL-C levels in individuals with familial hypercholesteremia below individual baseline values, ideally at a level at or below 100 mg/dL.

Connect with a study center

  • Atlantic Medical Group

    Clark, New Jersey 07066
    United States

    Site Not Available

  • Atlantic Medical Group

    Springfield, New Jersey 07081
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.